A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2.

BACKGROUND: Variation in an individual\u27s genetic status can impact the development of pancreatic ductal adenocarcinoma; however, the majority of familial pancreatic cancers (FPC) cannot yet be attributed to a specific inherited mutation. We present data suggesting a correlation between loss-of-function single nucleotide polymorphisms (SNPs) in an immune regulator gene, indoleamine-2,3-dioxygenase-2 (IDO2), and an increased risk of FPC. STUDY DESIGN: Germline DNA from patients who underwent resection for pancreatic ductal adenocarcinoma (n = 79) was sequenced for the IDO2 SNPs R248W and Y359Stop. Genotypes resulting in inactivation of IDO2 (Y325X homozygous, R248W homozygous) were labeled as homozygous, and the other genotypes were grouped as wild-type or heterozygous. Genotype distributions of each SNP were analyzed for Hardy-Weinberg deviation. A genotype frequency set from the 1000 Genomes Project (n = 99) was used as a genetic control for genotype distribution comparisons. RESULTS: A significant 2-fold increase in the overall prevalence of the Y359Stop homozygous genotype compared with the expected Hardy-Weinberg equilibrium was noted (p \u3c 0.05). Familial pancreatic cancer was noted in 15 cases (19%) and comparison of the FPC cohort set to the genetic control set showed a 3-fold increase in Y359Stop homozygous rates (p = 0.054). Overall in our cohort, the homozygous genotype group was associated with increased risk of FPC (odds ratio 5.4; 95% CI 1.6 to 17.6; p \u3c 0.01). Sex, age at diagnosis, and history of tobacco use were not found to be significantly associated with FPC. CONCLUSIONS: Our preliminary data suggest a strong association between the IDO2 inactivating Y359Stop SNP and an increased risk of FPC when compared with the control group. Future studies will evaluate the value of IDO2 genotyping as a prognostic, early detection marker for pancreatic ductal adenocarcinoma and a predictive marker for novel immune checkpoint therapies

A progressive postresection walking program significantly improves fatigue and health-related quality of life in pancreas and periampullary cancer patients.

BACKGROUND: As patients with pancreas and periampullary cancer (PPC) experience improved survival rates and longevity, the focus shifts toward living life while surviving cancer. Fatigue is the most commonly reported symptom in all cancer patients. Exercise has been found to effectively decrease fatigue levels and improve physical functioning in cancer patients. STUDY DESIGN: One hundred two patients with resected PPC consented to participate in this study and were randomized to either an intervention group (IG) or a usual care group (UCG). Subjects completed visual analog scales, the FACIT-Fatigue Scale and the Short Form-36v2 after surgery and again 3 to 6 months after hospital discharge. RESULTS: Patients in the IG and UCG were comparable with regard to demographics, comorbidities, cancer type and staging, type of resection, preoperative fatigue and pain levels, adjuvant therapy, and baseline walking distance. Patients in the IG had significantly improved scores on the FACIT-Fatigue Scale at study completion, improved fatigue and pain scores, as well as overall physical functioning and mental health composite scores. At study completion, participants in the IG were walking twice as far and were significantly more likely to have continued walking or another form of exercise as compared with the UCG. Using hierarchical cluster analysis, 3 mutually exclusive symptom groupings were identified in the cohort. Kaplan-Meier survival analysis did not indicate an overall survival benefit for the IG. CONCLUSIONS: This is the first prospective, randomized controlled trial to report that participation in a home walking program confers a significant benefit in resected PPC patients with regard to fatigue levels, physical functioning, and health-related quality of life

Patient Attitudes Toward a Physician Led Radiology Review: Improved Understanding of Medical Conditions and a Potential New Quality Metric

Objectives: We were interested in understanding patient perspectives regarding the importance of reviewing their imaging studies with a surgeon. Specific Aims: 1. What value do patients place on viewing their imaging? 2. Do patients have a better understanding of their disease and planned operation after a surgeon led review of imaging studies? 3. Do patients find viewing images an accessible educational tool?https://jdc.jefferson.edu/patientsafetyposters/1022/thumbnail.jp

Comfort Care and Symptom Management

Discuss Common Concerns in Supportive Care •Grief •Pain •Nausea / Constipation / Diarrhea •Anxiety / Depression •Fatigue / Tiredness •Decision makin

The Pathway to Low Outlier Status in Venous Thromboembolism Events: An Analysis of Pancreatic Surgery in ACS NSQIP

Introduction: Our institution’s hepatopancreaticobiliary service (HPBS) is a high-volume pancreatic surgery service, which has demonstrated consistently low rates of symptomatic venous thromboembolism (VTE) compared to similar institutions as reported by NSQIP. We sought to determine if the HPBS’s regimented multimodal VTE prophylaxis pathway plays a role in achieving consistently low VTE rates. Methods: We queried the ACS NSQIP Participant User File and our institution’s data from 2011-2016 for major pancreatic operations. We used Chi-squared analysis to compare the HPBS and national patient populations, and created a matched dataset based on preoperative patient factors. Univariate and multivariate analyses were performed on both the aggregate and matched data to determine independent risk factors for symptomatic VTE formation. Results: Among 36,435 NSQIP patients, 850 (2.3%) received surgery by the HPBS. VTE rates were significantly lower for the HPBS (2.0%) compared to the national cohort (3.5%) (p=0.018); this significance was seen in the matched cohort as well (p=0.040). Upon multivariate analysis, having an operation performed by the HPBS independently conferred lower odds of VTE formation in both the aggregate (OR=0.572, p=0.024) and matched (OR=0.530, p=0.041) cohorts. Discussion: The HPBS had statistically lower rates of symptomatic VTE compared to the national cohort as reported by NSQIP. We identified an independent protective effect of the HPBS on VTE formation, which we believe to be due, at least in part, to adherence to a high risk VTE prophylaxis pathway. This pathway could serve as a model for other institutions hoping to improve their VTE rates

Supportive Care Following Surgery

No Audio. Only PowerPoint slides

Optimizing cancer cure dialog: an analysis of pancreatic cancer patients\u27 views regarding survival and cure.

BACKGROUND: Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer. Clinicians commonly refer to surgical therapy as resection with curative intent. However, PDA cure rates after resection remain unknown and the definition of cure remains vague. We investigated how patients (the majority undergoing resection), family members, and clinicians understand the concept of cure, to better inform discussions with patients regarding PDA prognosis. METHODS: In a prospective survey, cohorts were asked to indicate the best definition of cure from three choices: 5-year survival endpoint (typically used in the literature), a biological endpoint without biochemical or radiographic signs of disease (similar to the NCI definition), or a practical endpoint where life span approximates similarly aged patients without PDA. Fleiss\u27 kappa statistic was calculated to measure inter-rater agreement. RESULTS: Patients, family members, and health care professionals (N = 200) agreed that renormalization of life expectancy was the preferred definition of cure in the context of pancreatic cancer. Inter-rater agreement was highest for the patient and family member groups (Fleiss\u27 kappa 0.27 and 0.40, respectively, P \u3c 0.001), while variability was observed between health care professionals (Fleiss\u27 kappa 0.11, P \u3c 0.001). CONCLUSIONS: In all groups surveyed, the probability for a normal life expectancy is the preferred long-term metric in patients with early-staged pancreatic cancer. Renormalization of life expectancy appears to be an important therapy goal for PDA patients and it is advisable to address this topic during clinical discussions

Asymptomatic Fluid Collections Following Distal Pancreatectomy – Is Intervention Warranted?

Objective To determine the incidence, associated factors, natural history, and interventions for FCs

16th Annual Pancreatic Cancer and Related Diseases Patient Symposium

On November 13, 2021, Charles J. Yeo, MD, FACS, and the multidisciplinary team of clinicians and scientists hosted the 16th Annual Pancreatic Cancer & Related Diseases Symposium. The video of the event is available here: vimeo.com/646517712/36786afe68. View our Pancreatic Cancer Program 2021 Update to learn more about Dr. Yeo and the team’s great work! PROGRAM Welcome and Program OverviewCharles J. Yeo, MD, FACSSamuel D. Gross Professor and Chair of Surgery Advances in FT in Treating Pancreatic CancerAdam Mueller, MD, PhDInstructor, Radiation Oncology KRAS Mutation Allele Frequency Impacts Prognosis in Pancreatic Ductal Adenocarcinoma Using Next-Generation SequencingHarish Lavu, MD, FACSProfessor of Surgery COVID-19 Pandemic and the JPTR: Results of the 2022-2021 Annual SurveyTheresa P. Yeo, PhD, AOCHP, ACNP-BC, FAANPProfessor, Jefferson College of Nursing Jefferson Pancreatic Cancer Research Institute UpdateAvinoam Nevler, MDAssistant Professor Pancreatic Cancer: Progress in Systemic TherapiesDaniel Lin, MD, MScAssistant Professor of Medical Oncology Pancreatic Neuroendocrine Tumors (PNETs): Overview and TreatmentWilbur B. Bowne, MDProfessor of Biochemistry and Molecular Biology Questions & Answers Survivor Tribute Photo & Survivor Testimonia